Get the Stockscreener App
13.07
1.32%
0.17
After Hours:
13.10
0.03
+0.23%
Capricor Therapeutics Inc stock is traded at $13.07, with a volume of 5.46M.
It is up +1.32% in the last 24 hours and down -30.92% over the past month.
Capricor Therapeutics Inc is a biotechnology company focused on advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat and prevent a wide range of diseases with targeted delivery.
See More
Previous Close:
$12.90
Open:
$12.64
24h Volume:
5.46M
Relative Volume:
1.56
Market Cap:
$594.29M
Revenue:
$27.10M
Net Income/Loss:
$-24.31M
P/E Ratio:
-11.17
EPS:
-1.17
Net Cash Flow:
$-33.33M
1W Performance:
-1.43%
1M Performance:
-30.92%
6M Performance:
+174.58%
1Y Performance:
+199.77%
1-Day Range:
$12.57
$13.53
1-Week Range:
$12.25
$14.50
52-Week Range:
$3.52
$23.40
Capricor Therapeutics Inc Stock (CAPR) Company Profile
Name
Capricor Therapeutics Inc
Sector
Industry
Phone
(310) 358-3200
Address
8840 WILSHIRE BLVD, BEVERLY HILLS, CA
Compare CAPR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CAPR
Capricor Therapeutics Inc
|
13.07 | 594.29M | 27.10M | -24.31M | -33.33M | -0.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-21-24 | Initiated | Piper Sandler | Overweight |
| May-17-24 | Initiated | Oppenheimer | Outperform |
| Jan-05-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-26-22 | Initiated | Ladenburg Thalmann | Buy |
| Dec-26-18 | Downgrade | Maxim Group | Buy → Hold |
| Jan-26-18 | Reiterated | H.C. Wainwright | Buy |
| Sep-15-17 | Reiterated | H.C. Wainwright | Buy |
| Feb-13-17 | Resumed | Rodman & Renshaw | Buy |
| Jul-06-16 | Resumed | H.C. Wainwright | Buy |
| Jun-15-16 | Initiated | ROTH Capital | Buy |
View All
Capricor Therapeutics Inc Stock (CAPR) Latest News
(CAPR) Trading Advice - Stock Traders Daily
Capricor Therapeutics (CAPR) Stock Dips Amid Biotech Sector Decl - GuruFocus.com
Capricor Therapeutics Inc (NASDAQ:CAPR) Short Interest Update - MarketBeat
Capricor Therapeutics (NASDAQ:CAPR) Trading Down 5.3%Here's Why - MarketBeat
Capricor Therapeutics (CAPR) Stock Drops Amid Volatile Biotech Sector - GuruFocus.com
High Growth Tech Stocks To Watch In December 2024 - Simply Wall St
RFK Jr. could prove a surprise boon for stem-cell stocks with pivotal year ahead - MarketWatch
Some Capricor Therapeutics, Inc. (NASDAQ:CAPR) Shareholders Look For Exit As Shares Take 27% Pounding - Simply Wall St
(CAPR) Pivots Trading Plans and Risk Controls - Stock Traders Daily
250,204 Shares in Capricor Therapeutics Inc (NASDAQ:CAPR) Purchased by Point72 Asset Management L.P. - MarketBeat
Deramiocel's Promise Brightens Capricor's Outlook, With Strings Attached (NASDAQ:CAPR) - Seeking Alpha
Capricor: Additional Deramiocel Data Bodes Well For Initiated Rolling BLA Submission - Seeking Alpha
Jones Trading keeps $40 target on Capricor Therapeutics By Investing.com - Investing.com UK
Piper Sandler maintains $35 target on Capricor shares By Investing.com - Investing.com Canada
Capricor Therapeutics (CAPR) Stock Surges Amid Positive Analyst Ratings - GuruFocus.com
TSX Venture Composite Index (JX) QuotePress Release - The Globe and Mail
Capricor Therapeutics to Present at Upcoming Investor Conferences - The Manila Times
Capricor Therapeutics to Present at Major Healthcare Conferences in December | CAPR Stock News - StockTitan
Walmart Inc (WMT-N) QuotePress Release - The Globe and Mail
Capricor Therapeutics Inc (NASDAQ:CAPR) Receives $34.50 Average Price Target from Analysts - MarketBeat
Capricor Therapeutics (CAPR) Sees Stock Surge Amid Positive Anal - GuruFocus.com
Pork Cutout (KMG25) Quote - The Globe and Mail
Capricor Therapeutics Executes Collaboration Agreement and Exclusive License Option with Janssen Biotech - Marketscreener.com
Capricor wins key EU designations for the lead asset - MSN
Capricor stock on watch after key EU designations (CAPR:NASDAQ) - Seeking Alpha
Capricor Therapeutics Granted Orphan Drug and ATMP Status for Deramiocel by European Medicines Agency - The Manila Times
(CAPR) Proactive Strategies - Stock Traders Daily
Capricor Therapeutics shares rated Buy by Jones Trading, boosted by DMD-CM therapy - Investing.com Canada
What is HC Wainwright's Estimate for CAPR FY2024 Earnings? - MarketBeat
KBW Bank Index (BKX) QuotePress Release - The Globe and Mail
Capricor Therapeutics Inc (NASDAQ:CAPR) Short Interest Down 14.6% in October - MarketBeat
Is Capricor Therapeutics (CAPR) the Best Multibagger Stock to Buy Heading into 2025? - Yahoo Finance
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q3 2024 Earnings Call Transcript - Insider Monkey
Capricor Therapeutics Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
Capricor Therapeutics Inc (CAPR) Quarterly 10-Q Report - Quartzy
10 Best Multibagger Stocks To Buy Heading into 2025 - Insider Monkey
Earnings call: Capricor outlines deramiocel's path to market for DMD treatment - Investing.com Canada
Capricor Therapeutics (NASDAQ:CAPR) Trading 7.3% Higher on Analyst Upgrade - MarketBeat
Cantor Fitzgerald Issues Positive Forecast for Capricor Therapeutics (NASDAQ:CAPR) Stock Price - MarketBeat
Decoding 12 Analyst Evaluations For Capricor Therapeutics - Benzinga
Capricor Therapeutics (CAPR) Reports Q3 Loss, Misses Revenue Estimates - MSN
Capricor Therapeutics Advances with Strategic Expansions - TipRanks
Capricor: Q3 Earnings Snapshot - San Antonio Express-News
Capricor Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times
Capricor Therapeutics earnings missed by $0.02, revenue fell short of estimates - Investing.com UK
Capricor Therapeutics Inc Stock (CAPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Capricor Therapeutics Inc Stock (CAPR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Litvack Frank | Director |
Dec 03 '24 |
Option Exercise |
1.10 |
20,391 |
22,430 |
46,278 |
| Nippon Shinyaku Co Ltd | 10% Owner |
Sep 20 '24 |
Buy |
5.36 |
2,798,507 |
14,999,998 |
7,090,351 |
| Musket David B | Director |
Aug 07 '24 |
Option Exercise |
1.39 |
34,000 |
47,260 |
81,692 |
| COLLIER EARL M JR | Director |
Apr 23 '24 |
Option Exercise |
1.39 |
30,000 |
41,700 |
56,856 |
| Musket David B | Director |
Apr 23 '24 |
Option Exercise |
1.39 |
16,156 |
22,457 |
47,692 |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):